ABEO Abeona Therapeutics Inc. Stock Quote

ABEO [NASD]

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	0.30%	Shs Outstand	147.38M	Perf Week	16.50%
Market Cap	25.78M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	-2.03%	Shs Float	124.15M	Perf Month	-33.94%
Income	-84.90M	PEG	-	EPS next Q	-0.08	Inst Own	24.20%	Short Float	3.25%	Perf Quarter	-26.44%
Sales	3.00M	P/S	8.59	EPS this Y	5.10%	Inst Trans	-12.39%	Short Ratio	1.99	Perf Half Y	-80.33%
Book/sh	0.49	P/B	0.37	EPS next Y	27.30%	ROA	-46.00%	Target Price	2.67	Perf Year	-86.76%
Cash/sh	0.31	P/C	0.57	EPS next 5Y	-	ROE	-69.90%	52W Range	0.13 - 1.92	Perf YTD	-46.59%
Dividend	-	P/FCF	-	EPS past 5Y	-6.20%	ROI	-171.40%	52W High	-90.62%	Beta	1.54
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	27.50%	Gross Margin	-	52W Low	38.14%	ATR	0.03
Employees	90	Current Ratio	3.30	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	39.51	Volatility	19.38% 13.51%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-155.80%	Profit Margin	-	Rel Volume	0.82	Prev Close	0.16
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.03M	Price	0.18
Recom	2.30	SMA20	-12.93%	SMA50	-30.96%	SMA200	-71.38%	Volume	1,630,042	Change	11.18%

Nov-11-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

Sep-18-20

Initiated

B. Riley FBR

Buy

Feb-10-20

Initiated

SVB Leerink

Outperform

Dec-10-19

Resumed

Cantor Fitzgerald

Neutral

$2 → $4

Aug-15-19

Downgrade

Maxim Group

Buy → Hold

Aug-12-19

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$29 → $2

Jul-26-19

Downgrade

Mizuho

Buy → Neutral

$17 → $4

Jun-27-19

Initiated

Mizuho

Buy

Oct-12-18

Initiated

Mizuho

Buy

$17

Jun-05-18

Initiated

Seaport Global Securities

Buy

$29

Nov-08-17

Initiated

SunTrust

Buy

$26

Oct-16-17

Reiterated

H.C. Wainwright

Buy

$20 → $30

Oct-11-17

Reiterated

Cantor Fitzgerald

Overweight

$21 → $34

Oct-10-17

Initiated

Citigroup

Buy

$32

Oct-05-17

Reiterated

Maxim Group

Buy

$17 → $35

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$23

Jul-18-17

Reiterated

Maxim Group

Buy

$14 → $17

Jun-22-17

Resumed

Jefferies

Buy

$22

Jan-06-17

Initiated

Jefferies

Buy

Sep-29-16

Reiterated

Maxim Group

Buy

$8 → $14

May-13-22 07:30AM	Abeona Therapeutics Reports First Quarter 2022 Financial Results GlobeNewswire
May-12-22 02:47PM	AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals Zacks +15.09%
May-11-22 02:28PM	Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates Zacks -14.69%
May-10-22 02:36PM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates Zacks
11:37AM	Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down Zacks
May-06-22 03:48PM	Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y Zacks -9.37%
03:38PM	ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates Zacks
May-04-22 07:30AM	Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates GlobeNewswire
May-03-22 07:00AM	Dianthus, a new $100M startup, aims to make autoimmune treatments easier American City Business Journals
Apr-29-22 09:00AM	Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire -7.07%
07:30AM	Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock GlobeNewswire
Apr-19-22 10:51AM	Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth? Simply Wall St.
Mar-31-22 07:30AM	Abeona Therapeutics Announces Strategy Update and 2021 Financial Results GlobeNewswire
Mar-28-22 11:20AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit GlobeNewswire
Mar-14-22 07:30AM	Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL Study of EB-101 in RDEB GlobeNewswire
Jan-25-22 10:00AM	Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing Zacks +7.57%
Dec-22-21 07:30AM	Abeona Therapeutics Issues Letter to Shareholders GlobeNewswire
Dec-17-21 09:00AM	Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire -39.97%
Dec-16-21 04:01PM	Abeona Therapeutics Announces Public Offering of Common Stock and Warrants GlobeNewswire -6.39%
Dec-02-21 07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday InvestorPlace
Nov-19-21 10:00AM	Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a Turnaround Zacks
Nov-18-21 07:30AM	Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa GlobeNewswire -9.76%
Nov-17-21 07:30AM	Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference GlobeNewswire
Nov-16-21 07:30AM	Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference GlobeNewswire
Nov-15-21 07:45AM	Abeona Therapeutics Reports Third Quarter Financial Results GlobeNewswire
07:12AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday InvestorPlace
Oct-21-21 07:30AM	Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit GlobeNewswire
06:21AM	Abeona Therapeutics (NASDAQ:ABEO) investors are sitting on a loss of 90% if they invested three years ago Simply Wall St.
Oct-13-21 07:30AM	Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses GlobeNewswire
Oct-12-21 07:30AM	Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality GlobeNewswire
Sep-21-21 04:01PM	Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings GlobeNewswire
Sep-07-21 07:30AM	Abeona Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-10-21 07:30AM	Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer GlobeNewswire
Jul-28-21 04:01PM	Abeona Therapeutics Reports Second Quarter Financial Results GlobeNewswire
07:30AM	Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA) GlobeNewswire
Jul-26-21 07:30AM	Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy GlobeNewswire
06:12AM	Abeona Reports Positive Data for Sanfilippo Syndrome Treatment TheStreet.com
Jul-23-21 07:30AM	Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL Study for Recessive Dystrophic Epidermolysis Bullosa GlobeNewswire
Jul-07-21 12:02PM	Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder Benzinga
07:30AM	Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting GlobeNewswire
Jun-14-21 10:00AM	10 Penny Stocks Robinhood Traders are Buying in 2021 Insider Monkey
Jun-02-21 07:30AM	Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-26-21 07:30AM	Abeona Therapeutics Issues Letter to Stockholders GlobeNewswire +10.74%
May-25-21 07:30AM	Abeona Therapeutics Appoints Head of Research & Clinical Development GlobeNewswire
06:45AM	Abeona Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-18-21 07:30AM	Abeona Therapeutics Reports First Quarter Financial Results GlobeNewswire +14.71%
May-11-21 06:06AM	Moving Average Crossover Alert: Abeona Therapeutics (ABEO) Zacks
Apr-20-21 07:30AM	Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting GlobeNewswire
Apr-19-21 07:30AM	Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors GlobeNewswire -5.37%
Mar-25-21 07:30AM	Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors GlobeNewswire +5.62%
Mar-24-21 05:15PM	Abeona Therapeutics (ABEO) Reports Q4 Loss, Lags Revenue Estimates Zacks -6.32%
04:01PM	Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress GlobeNewswire
Mar-23-21 12:41PM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire -6.86%
Mar-22-21 07:30AM	Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer GlobeNewswire -6.42%
Mar-11-21 11:22PM	Abeona Therapeutics' (NASDAQ:ABEO) Shareholders Are Down 85% On Their Shares Simply Wall St.
Feb-25-21 11:33AM	Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks TipRanks +13.18%
Feb-22-21 07:30AM	Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -7.47%
Feb-12-21 11:36AM	New Positive Phase 1/2 Interim Data Presented at WORLDSymposium Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeonas ABO-102 Gene Therapy GlobeNewswire -11.90%
Feb-02-21 07:30AM	Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium GlobeNewswire
Jan-25-21 07:30AM	Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) GlobeNewswire +9.91%
Jan-12-21 08:50AM	Do Options Traders Know Something About Abeona (ABEO) Stock We Don't? Zacks
Dec-21-20 12:20PM	Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium GlobeNewswire
Dec-14-20 09:44PM	Is ABEO A Good Stock To Buy Now? Insider Monkey
Dec-01-20 10:06AM	Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer Zacks -6.17%
09:09AM	Is the Options Market Predicting a Spike in Abeona (ABEO) Stock? Zacks
Nov-27-20 08:25AM	HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts Zacks +17.02%
Nov-24-20 03:10PM	Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases Zacks
03:08PM	Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology Zacks
03:07PM	Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate Zacks
Nov-18-20 11:24AM	Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint Zacks +9.38%
Nov-17-20 01:16PM	Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study Zacks
Nov-12-20 05:21AM	How Much Are Abeona Therapeutics Inc. (NASDAQ:ABEO) Insiders Spending On Buying Shares? Simply Wall St. -6.92%
Nov-09-20 05:55PM	Abeona Therapeutics (ABEO) Reports Q3 Loss Zacks
04:05PM	Abeona Therapeutics Reports Third Quarter Financial Results GlobeNewswire
Oct-27-20 06:30AM	Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer GlobeNewswire -6.35%
Oct-14-20 10:58PM	Abeona Therapeutics Inc (ABEO): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Oct-06-20 04:01PM	Abeona Therapeutics Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan GlobeNewswire +11.93%
Sep-28-20 09:27AM	Abeona Therapeutics Announces Leadership and Board Transitions GlobeNewswire -41.40%
Sep-18-20 11:08AM	Why Abeona Therapeutics Is Trading Higher Today Benzinga +6.12%
09:31AM	Benzinga's Top Upgrades, Downgrades For September 18, 2020 Benzinga
Sep-08-20 04:05PM	Abeona Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-01-20 06:29AM	Are Institutions Heavily Invested In Abeona Therapeutics Inc.'s (NASDAQ:ABEO) Shares? Simply Wall St.
Aug-17-20 07:00AM	Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease GlobeNewswire
Aug-10-20 04:01PM	Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates GlobeNewswire
Aug-04-20 11:36AM	Did Hedge Funds Make The Right Call On Abeona Therapeutics Inc (ABEO) ? Insider Monkey
Jul-10-20 07:30AM	Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting GlobeNewswire -10.15%
Jul-09-20 09:10AM	Abeona Restarts Enrollment in Connective Tissue Disorder Study Zacks
07:30AM	Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer GlobeNewswire
Jul-08-20 07:30AM	Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies GlobeNewswire
Jul-03-20 07:48AM	Here's Why We're Watching Abeona Therapeutics's (NASDAQ:ABEO) Cash Burn Situation Simply Wall St.
Jun-23-20 11:59AM	Hedge Funds Still Crazy About Abeona Therapeutics Inc (ABEO)? Insider Monkey
Jun-18-20 07:30AM	Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting GlobeNewswire
Jun-17-20 07:30AM	Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors GlobeNewswire
Jun-08-20 09:11AM	Edited Transcript of ABEO earnings conference call or presentation 7-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-28-20 11:30AM	Is Abeona Therapeutics (ABEO) Outperforming Other Medical Stocks This Year? Zacks
08:30AM	Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference GlobeNewswire
May-08-20 12:58PM	Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y Zacks +15.45%
May-07-20 01:59PM	Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates Zacks
May-06-20 04:14PM	Abeona Therapeutics Reports First Quarter Financial Results and Business Updates GlobeNewswire
Apr-29-20 11:08AM	Moving Average Crossover Alert: Abeona Therapeutics Zacks

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Malley Brendan M.	SVP, General Counsel	Dec 06	Sale	0.57	8,880	5,035	204,750	Dec 08 07:05 PM
O'Malley Brendan M.	SVP, General Counsel	Nov 05	Sale	0.89	8,880	7,894	213,630	Nov 05 07:00 PM
O'Malley Brendan M.	SVP, General Counsel	Oct 11	Sale	0.90	25,734	23,271	222,510	Oct 13 07:08 PM
O'Malley Brendan M.	SVP, General Counsel	Oct 08	Sale	1.05	22,763	23,915	248,244	Oct 08 08:31 PM
CARR EDWARD	Chief Financial Officer	Oct 08	Sale	1.05	29,122	30,596	400,169	Oct 08 08:29 PM
Wider Todd	Director	Oct 07	Sale	0.97	25,000	24,150	0	Oct 08 08:33 PM
O'Malley Brendan M.	SVP, General Counsel	Oct 05	Sale	1.05	2,447	2,569	271,007	Oct 08 08:31 PM
Amoroso Michael	Chief Executive Officer	Sep 30	Sale	1.09	45,409	49,382	604,637	Oct 04 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience